Myeloid SASP Reprogramming as a Lever to Reverse Age‑Driven Epigenetic Field Cancerization in the Colon

Hypothesis

Aged colonic myeloid cells secrete a SASP that directly drives epigenetic silencing of mismatch repair (MMR) genes in neighboring epithelial cells via TGF‑β‑SMAD signaling, establishing a field cancerization phenotype. Pharmacologic inhibition of myeloid TGF‑β production or enhancement of SMAD7 in epithelium will restore MMR expression, reduce methylation, and suppress tumorigenesis even in aged hosts.

Mechanistic Rationale

1. Immunosenescence leads to accumulation of CD11b⁺Ly6C^high monocytes that adopt an immunosuppressive, SASP‑rich phenotype (see 2).
2. These cells release high levels of TGF‑β and IL‑6, which activate SMAD2/3 in colonic epithelium (see 1).
3. Persistent SMAD signaling recruits DNMT1 and HDAC complexes to the promoters of MLH1, MSH2, and MSH6, causing CpG island methylation and transcriptional silencing (novel link).
4. Loss of MMR creates a mutator phenotype and field‑wide chromatin instability, visible as nanoscale alterations (see 3).
5. The resulting epigenetic field precedes any APC or KRAS mutation, explaining why biological age acceleration predicts CRC risk independently of genotype (see 4).

Testable Predictions

• In aged mice, myeloid‑specific TGF‑β neutralization will decrease MLH1 promoter methylation in crypt epithelia by >30% compared with IgG controls.
• Adoptive transfer of young myeloid cells into old recipients will rescue MMR expression and reduce aberrant crypt foci formation.
• Pharmacologic activation of SMAD7 (e.g., via AAV‑SMAD7) in epithelium will mimic the effect of myeloid TGF‑β blockade, confirming epithelial SMAD signaling as the critical node.
• Conversely, overexpression of TGF‑β in young myeloid cells will prematurely silence MMR genes and induce field cancerization markers.

Experimental Design

1. Model: Use ER‑flow mice (aged 18‑20 mo) and young (8‑10 mo) controls.
2. Interventions:
   • a. Anti‑TGF‑β antibody (1D11) administered intraperitoneally twice weekly for 4 weeks.
   • b. Clodronate liposomes to deplete myeloid cells, followed by adoptive transfer of TGF‑β‑deficient myeloid progenitors.
   • c. AAV8‑SMAD7 delivered via colonoscopy‑like retrograde infusion.
3. Readouts:
   • Bisulfite sequencing of MLH1/MSH2 promoters in laser‑captured crypt epithelium.
   • Immunofluorescence for γH2AX and 53BP1 as DNA damage markers.
   • Count of aberrant crypt foci (ACF) after azoxymethane challenge.
   • Flow cytometry of colonic myeloid subsets and SASP cytokine profiling (Luminex).
4. Statistical Plan: Power analysis targets n = 10 per group to detect 25% methylation difference with α = 0.05, power = 0.8. Two‑way ANOVA with post‑hoc Tukey.

Potential Outcomes & Interpretation

• Support: Significant demethylation and restored MMR expression alongside reduced ACF would confirm myeloid‑derived TGF‑β as an epigenetic driver of field cancerization.
• Refute: No change in methylation despite myeloid manipulation would suggest alternative SASP components (e.g., IL‑6/JAK‑STAT) or stromal mediators dominate, redirecting focus.
• Unexpected: Overactivation of SMAD7 causing hyperplasia would indicate context‑dependent tumor suppressor roles, prompting dose‑response titration.

By directly testing whether reprogramming the myeloid SASP can reset epithelial epigenetic fidelity, this hypothesis moves immune aging from a passive risk factor to a mechanistic lever that, if manipulated, could delay or prevent the epigenetic field that precedes colorectal carcinogenesis.